NGS

Disease-Focused Next Generation Sequencing (NGS)

Testing for somatic (acquired) gene mutations can help better understand a range of blood and solid tumor cancers. While insights continue to uncover new gene associations and their impact across the continuum of patient care, especially in treatment selection, siParadigm provides panels that deliver the most actionable and relevant information for clinicians.

Solid Tumor Panels

Oncomine™ Focus Panel (52 Genes)

Hotspot Genes (35)

CNVs (19)

Fusion Driver Genes (23)

AKT1

ERBB4

JAK2

 PIK3CA

ALK

FGFR3

ABL1

ETV5

RAF1

ALK

ESR1

JAK3

 RAF1

AR

FGFR4

ALK

FGFR1

RET

AR

FGFR2

KIT

 RET

BRAF

KIT

AKT3

FGFR2

ROS1

BRAF

FGFR3

 KRAS

 ROS1

CCND1

KRAS

AXL

FGFR3

  

CDK4

GNA11

 MAP2K1

 SMO

CDK4

MET

BRAF

MET

  

CTNNB1

GNAQ

 MAP2K2

  

CDK6

MYC

EGFR

NTRK1

  

DDR2

HRAS

 MET

  

EGFR

MYCN

ERBB2

NTRK2

  

EGFR

IDH1

 MTOR

  

ERBB2

PDGFRA

ERG

NTRK3

  

ERBB2

IDH2

 NRAS

  

FGFR1

PIK3CA

ETV1

PDGFRA

  

ERBB3

JAK1

PDGFRA

  

FGFR2

  

ETV4

PPARG

  

 

  • Turn Around Time (TAT): 7 – 10 days
  • Specimen Requirement: FFPE blocks, tissue sections or extracted DNA and RNA are acceptable.
  • In case of FFPE sections, 5-10 sections are recommended.
  • Previously extracted DNA is acceptable when transported on ice and RNA on dry ice. A minimum of 20 μl of each DNA and RNA with a concentration of at least 5ng/μl and an OD260/280 ratio of 1.7-1.9 and 2.0-2.1 respectively, obtained on a spectrophotometer is required.

NSCLC and CRC NGS Panel (22 Genes)

ALK
AKT1
BRAF
CTNNB1
DDR2
EGFR
ERBB2
ERBB4
FBX7
FGFR1
FGFR2
FGFR3
KRAS-Extended
MAP2K1
MET
NOTCH1
NRAS
PTEN
PIK3CA
STKI1
SMAD4
TP53

Hereditary Cancer Assessment Panel

BRCA1
BRCA2

Hematology Panels

AML Panel (19 Genes)

ASXL1
BRAF
CBL
CEBPA
DNMT3A
FLT3
GATA2
IDH1
IDH2
JAK2
KIT
KRAS
NPM1
NRAS
PTPN11
RUNX1
TET2
TP53
WT1

CLL Panel (17 Genes and Targeted Regions)

ATM
(exons 2-63)
BTK
(exons 14-16)
BIRC3
(exons 6-8)
CARD11
(exons 2-8)
CD79B
(exons 4-5)
DDX3X
(exons 7-9, 11, 14)
FBXW7
(exons 6-9)
MAPK1
(exon 7)
MYD88
(exons 3-5)
NOTCH1
(hotspots)
PIK3CA
(hotspots)
PIK3CD
(hotspots)
PTEN
(hotspots)
PTPN6
(hotspots)
SF3B1
(hotspots)
TP53
(exons 2-11)
XPO
(exons 12, 13, 15)

CMML Panel (18 Genes)

ASXL1
CBL
CSF3R
DNMT3A
EZH2
JAK3
KRAS
MPL
NOTCH1
NRAS
RUNX1
SETBP1
SF3B1
SRSF2
TET2
TP53
U2AF1
ZRSR2

MDS Panel (19 Genes)

ASXL1
DNMT3A
ETV6
EVI1
EZH2
IDH1
IDH2
KDM6A/UTX
KRAS
NRAS
RPS14
RUNX1
SETBP1
SF3B1
SRSF2
TET2
TP53
U2AF1
ZRSR2

MPN Panel (16 Genes)

ASXL1
CALR
CSF3R
DNMT3A
EZH2
JAK2
JAK3
IDH1
IDH2
MPL
NRAS
SH2B3
SETBP1
SRSF2
TET2
TP53

Pan-Myeloid Panel (43 Genes)

ASXL1
BRAF
CALR
CBL
CDK2NA
CEBPA
CSF1R
CSF3R
DNMT3A
ETV6
EVI1
EZH2
FBXW7
FGFR1
FGFR2
FGFR3
FLT3
GATA2
IDH1
IDH2
JAK2
JAK3
KDM6A/UTX
KIT
KRAS
MPL
MYD88
NOTCH1
SNPM1
NRAS
PDGFRA
PTPN11
RPS14
RUNX1
SETBP1
SF3B1
SH2B3
SRSF2
TET2
TP53
U2AF1
WT1
ZRSR2

"While we have many laboratories to choose from, we consider siParadigm to be the most reliable. Contact with a hematopatholgist is rapid and informative."

Barry Kaplan, MD, PhD
Oncologist/Hematologist, Queens Medical Assoc.

Discover more.

A Model Experience

With core values rooted in service and integrity, our leadership team sets the bar high.

We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.

Accredited and Certified

siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).

We also hold select state licensure where required.